| Identification | Back Directory | [Name]
N-[4-Methyl-3-(2',3',5',6'-tetrahydro-4-oxospiro[2H-1,3-benzoxazine-2,4'-[4H]pyran]-7(3H)-yl)phenyl]-2-(trifluoromethyl)-4-pyridinecarboxamide | [CAS]
2695505-82-7 | [Synonyms]
RAF-IN-1
N-[4-Methyl-3-(2',3',5',6'-tetrahydro-4-oxospiro[2H-1,3-benzoxazine-2,4'-[4H]pyran]-7(3H)-yl)phenyl]-2-(trifluoromethyl)-4-pyridinecarboxamide
4-Pyridinecarboxamide, N-[4-methyl-3-(2',3',5',6'-tetrahydro-4-oxospiro[2H-1,3-benzoxazine-2,4'-[4H]pyran]-7(3H)-yl)phenyl]-2-(trifluoromethyl)- | [Molecular Formula]
C26H22F3N3O4 | [MOL File]
2695505-82-7.mol | [Molecular Weight]
497.47 |
| Hazard Information | Back Directory | [Uses]
RAF-IN-1 is a potent b/cRAF inhibitor with an IC50s of 3.8 nM, 36 nM, 29.4 nM for cRAF, bRAFwt, and bRAFV600E. RAF-IN-1 shows cell growth inhibition with GI50s of 3.4 and 2.9 nM for H358 and A375 cell line bearing bRAFV600E mutation, respectively[1]. | [IC 50]
BRafV600E: 29.4 nM (IC50); BRAFWT: 36 nM (IC50); c-Raf: 3.8 nM (IC50) | [References]
[1] Zhao P, et al. Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers. Eur J Med Chem. 2022;228:114040. DOI:10.1016/j.ejmech.2021.114040 |
|
|